Post
JAMA Neurology
jamaneurology.com
did:plc:i5h3b76gf3tu5vfp4ehdkcrw
In women with multiple sclerosis, disease-modifying therapy management during pregnancy increased relapse risk, particularly in patients receiving natalizumab with prolonged interruption or fingolimod. ja.ma/3KOHJGd
2025-10-18T11:00:02.754Z